v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) is another potential target for advanced NSCLC treatment, since mutations in BRAF have been shown to play a role in tumorigenesis in NSCLC [6]. Here, BRAF is linked to non-small cell lung carcinoma.